Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Torregrosa C, Pernot S, Vaflard P, Perret A, Tournigand C, Randrian V, Doat S, Neuzillet C, Moulin V, Stouvenot M, Roth G, Darbas T, Auberger B, Godet T, Jaffrelot M, Lambert A, Dubreuil O, Gluszak C, Bernard-Tessier A, Turpin A, Palmieri LJ, Bouche O, Goujon G, Lecomte T, Sefrioui D, Locher C, Grados L, Gignoux P, Trager S, Nassif E, Saint A, Hammel P, Lecaille C, Bureau M, Perrier M, Botsen D, Bourgeois V, Taieb J, Auclin E. Torregrosa C, et al. Among authors: bouche o. Int J Cancer. 2022 Dec 1;151(11):1978-1988. doi: 10.1002/ijc.34166. Epub 2022 Jul 14. Int J Cancer. 2022. PMID: 35833561
Metastatic colorectal cancer.
Bouche O, Conroy T, Michel P, Penna C, Tournigand C. Bouche O, et al. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S30-2S42. Gastroenterol Clin Biol. 2006. PMID: 17151561 Free article. Review. No abstract available.
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Laurent-Puig P, et al. Among authors: bouche o. J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884556
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, Laurent-Puig P. Boige V, et al. Among authors: bouche o. J Clin Oncol. 2010 May 20;28(15):2556-64. doi: 10.1200/JCO.2009.25.2106. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385995 Clinical Trial.
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY. Bennouna J, et al. Among authors: bouche o. Clin Colorectal Cancer. 2012 Mar;11(1):38-44. doi: 10.1016/j.clcc.2011.05.002. Epub 2011 Jul 29. Clin Colorectal Cancer. 2012. PMID: 21803002 Clinical Trial.
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, Rougier P, Gasmi M, Castaing M, Abbas M, Michel P, Gargot D, Azzedine A, Lombard-Bohas C, Geoffroy P, Denis B, Pignon JP, Bedenne L, Bouché O; Fédération Francophone de Cancérologie Digestive (FFCD) 2000–05 Collaborative Group. Ducreux M, et al. Among authors: bouche o. Lancet Oncol. 2011 Oct;12(11):1032-44. doi: 10.1016/S1470-2045(11)70199-1. Epub 2011 Sep 6. Lancet Oncol. 2011. PMID: 21903473 Clinical Trial.
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Among authors: bouche o. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, Cretin J, Locher C, Bouché O, Breysacher G, Charneau J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Mitry E. Aparicio T, et al. Among authors: bouche o. J Clin Oncol. 2013 Apr 10;31(11):1464-70. doi: 10.1200/JCO.2012.42.9894. Epub 2013 Mar 4. J Clin Oncol. 2013. PMID: 23460711 Clinical Trial.
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Conroy T, et al. Among authors: bouche o. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Lancet Oncol. 2014. PMID: 24556041 Clinical Trial.
410 results